한글목차

골다공증은 골량의 감소와 골조직의 미세구조의 저하를 특징으로 하는 전신성 골격계 질환으로 정의되며, 뼈의 취약성과 골절이 발생하기 쉬운 소인을 유발합니다. 흔한 골절 부위는 척추, 고관절, 팔뚝 원위부, 상완골 근위부 등입니다. 이러한 골절은 일반 인구의 이환율의 주요 원인이며, 환자의 회복에 시간이 오래 걸리고, 대부분 지속적인 간병이 필요합니다.

이 보고서는 주요 7개국 시장의 골다공증 위험인자, 동반질환, 세계 및 과거 역학 동향을 개괄하고, 진단된 발병 사례와 진단된 유병률에 대한 10년간의 역학 예측 등을 정리했습니다.

목차

제1장 골다공증 : 주요 요약

제2장 서론

제3장 질환 개요

• 병인과 병태생리학
  • 병인
  • 병태생리학
• 분류
• 예후

제4장 역학

• 질환의 배경
• 위험요인과 합병증
• 세계와 역사 동향
• 주요 7개국 시장 예측 조사 방법
• 출전
• 예측의 전제조건과 방법
• 예측의 전제조건과 방법 : 골다공증 유병률
• 예측의 전제조건과 방법 : 골다공증 진단 사례
• 예측의 전제조건과 방법 : 원발성 골다공증 및 이차성 골다공증의 총 유병 사례 및 진단된 유병 사례.
• 예측의 전제조건과 방법 : 총 유병률 및 진단된 1형 및 2형 골다공증 유병률.
• 예측의 전제조건과 방법 : 글루코코르티코이드 사용으로 인한 이차성 골다공증의 총 유병 사례 및 진단된 유병 사례
• 예측의 전제조건과 방법 : 골감소증 총 유병 사례 수
• 예측의 전제조건과 방법 : 골감소증 진단 사례
• 골다공증 역학적 예측(2023-2033년)
• 골다공증 유병률
• 논의
• 역학적 예측 인사이트
• COVID-19의 영향
• 분석의 한계
• 분석의 강점

제5장 질병 관리

• 진단과 치료 개요
• 질병 관리에 관한 KOL 인사이트

제6장 현재 치료 옵션

제7장 미충족 요구와 기회 평가

• 개요
• 진단 비율과 치료율 향상
• 골다공증 치료 준수율 향상
• 장기 약물 치료 안전성 프로파일이 향상

제8장 연구개발 전략

• 개요
• 바이오시밀러 개발에 주력
• 향후 골다공증 치료를 위한 Wnt 신호전달 경로 연구
• 임상시험 설계

제9장 파이프라인 평가

• 개요
• 임상 개발 중인 유망한 의약품

제10장 파이프라인 평가 분석

• 개요
• 경쟁력 평가

제11장 현재 참여 기업과 향후 참여 기업

• 개요
• 거래 동향

제12장 시장 전망

• 세계 시장
• 미국
• EU 5개국
• 일본

제13장 부록

영문목차

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Osteoporosis market through 2033.

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, predisposing a person to bone fragility and susceptibility to fracture. Common sites of fracture include the spine, hip, distal forearm, and proximal humerus. Such fractures are a major cause of morbidity in the general population and a patient's recovery can be slow, with many requiring full-time care.

Major drivers of growth in the osteoporosis market during the forecast period include the following -

• The increased use of Evenity across the 7MM, which will be accelerated by growing physician familiarity and clinical experience following recent launch
• The rising use of anabolic therapies, which are typically more expensive than anti-resorptive agents, in particular low-cost bisphosphonates
• An increase in the number of people with osteoporosis, in line with the growth of the global aging population

Major barriers to growth in the osteoporosis market during the forecast period will include the following -

• High cost of anabolic therapies and dual-action Evenity compared to affordable bisphosphonates, which have established long-term safety and efficacy profiles
• Loss of patent protection and/or market exclusivity for some products during the forecast period, and the subsequent launches of biosimilars and generics; this includes the expected launch of denosumab biosimilars in 2025 and 2027 across the 7MM, which will take substantial market share from marketed Prolia/Pralia
• Low patient compliance with many osteoporosis therapies due to adverse side effects, frequent administration leading to lifestyle disruption, the discomfort of regular subcutaneous or intravenous injections, as well as patients missing treatment appointments, especially due to other medical complications in older patients

Scope

• Overview of osteoporosis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized osteoporosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the osteoporosis therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for osteoporosis treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global osteoporosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM osteoporosis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM osteoporosis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Osteoporosis: Executive Summary

• 1.1 The osteoporosis market will show steady growth during the forecast period, reaching sales of $17.9B in 2033
• 1.2 Biosimilars and generics are forecast to take substantial market share from originator drugs during the forecast period
• 1.3 Poor compliance presents a significant unmet need in the osteoporosis landscape
• 1.4 Improved long-term safety profiles are necessary for future pipeline osteoporosis therapies
• 1.5 Entera Bio's oral teriparatide is projected to enter the US market during the forecast period
• 1.6 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related Reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification
• 3.3 Prognosis

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
• 4.5 Sources
• 4.6 Forecast assumptions and methods.
  • 4.6.1 7MM
• 4.7 Forecast assumptions and methods: total prevalent cases of osteoporosis.
  • 4.7.1 US
  • 4.7.2 France, Germany, Italy, Spain, and UK
  • 4.7.3 Japan
• 4.8 Forecast assumptions and methods: diagnosed prevalent cases of osteoporosis.
  • 4.8.1 US
  • 4.8.2 France
  • 4.8.3 Germany
  • 4.8.4 Italy, Spain, and UK
  • 4.8.5 Japan
• 4.9 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of primary osteoporosis and secondary osteoporosis.
  • 4.9.1 7MM
• 4.10 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of type 1 and type 2 osteoporosis.
  • 4.10.1 7MM
• 4.11 Forecast assumptions and methods: total prevalent cases and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use
  • 4.11.1 7MM
• 4.12 Forecast assumptions and methods: total prevalent cases of osteopenia.
  • 4.12.1 US
  • 4.12.2 France and Germany
  • 4.12.3 Italy
  • 4.12.4 Spain
  • 4.12.5 UK
  • 4.12.6 Japan
• 4.13 Forecast assumptions and methods: diagnosed prevalent cases of osteopenia.
  • 4.13.1 7MM
• 4.14 Epidemiological forecast for osteoporosis (2023-33)
  • 4.14.1 Total prevalent cases of osteoporosis
• 4.15 Age-specific total prevalent cases of osteoporosis
• 4.16 Sex-specific total prevalent cases of osteoporosis
• 4.17 Total prevalent cases of osteoporosis by primary and secondary osteoporosis
• 4.18 Total prevalent cases of primary osteoporosis by type
• 4.19 Total prevalent cases of osteoporosis secondary to glucocorticoid use
• 4.20 Diagnosed prevalent cases of osteoporosis.
• 4.21 Age-specific diagnosed prevalent cases of osteoporosis
• 4.22 Sex-specific diagnosed prevalent cases of osteoporosis
• 4.23 Diagnosed prevalent cases of osteoporosis by primary and secondary osteoporosis.
• 4.24 Diagnosed prevalent cases of primary osteoporosis by type.
  • 4.24.1 Diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
• 4.25 Discussion
• 4.26 Epidemiological forecast insight
• 4.27 COVID-19 impact.
• 4.28 Limitations of the analysis
• 4.29 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
  • 5.1.1 Diagnosis of osteoporosis
  • 5.1.2 Treatment guidelines for osteoporosis
  • 5.1.3 Treatment among osteoporosis subtypes
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Improved diagnosis and treatment rates
• 7.3 Higher rates of compliance with osteoporosis treatment
• 7.4 Better safety profiles for long-term drug treatment

8 R&D Strategies

• 8.1 Overview
• 8.2 Focus on the development of biosimilars
• 8.3 Investigating the Wnt signaling pathway for future osteoporosis therapies
• 8.4 Clinical trials design
  • 8.4.1 Improvements in patient representation in osteoporosis clinical trials
  • 8.4.2 Novel biomarkers for osteoporosis assessment in clinical trials

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key Events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and Barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting Methodology
• 13.4 Primary Research - KOLs Interviewed for This Report
  • 13.4.1 Elizabeth Shane, MD
• 13.5 Primary Research - Prescriber Survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Vice President of Disease Intelligence and Epidemiology
  • 13.6.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us